

**REMARKS**

In response to the outstanding Restriction Requirement mailed March 20, 2008, Applicants elect Invention 7, claim 100, for examination, with traverse. Applicants respectfully request that Inventions 7, 9 and 11 be combined into a single group because in each, the molecule is an allergen, a viral antigen, or a tumor antigen. No justification was provided to restrict the molecule into three separate groups. Thus, Applicants propose that Invention 7, 9 and 11 be combined into a single Group for restriction purposes, and that if an election of species is necessary, Applicants elect the invention in which the molecule is an allergen.

Claims 81-137 have been cancelled without prejudice and new claims 138-169 have been added. No new matter has been added. New claims 138-169 are directed to the invention of claim 100. Therefore, claims 138-169 read on the elected invention.

Applicants acknowledge the mention of Ko *et al.*, J. Formos. Med. Assoc., 96(7):517-524. New claims 138-169 are patentable over this reference.

Claims 138-169 are currently pending.


**CONCLUSION**

Applicant believes that the claims are in condition for allowance.

Should any fees be required by the present Reply, the Commissioner is hereby authorized to charge Deposit Account 19-4293.

Respectfully submitted,

Date: 5-20-08  
Customer Number: 27890  
STEPTOE & JOHNSON LLP  
1330 Connecticut Ave., NW  
Washington, DC 20036  
Tel: 202-429-3000  
Fax: 202-429-3902

  
Harold H. Fox  
Reg. No. 41,498